AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.Barrons • 02/27/26
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/26/26
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of PresbyopiaPRNewsWire • 02/25/26
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 02/23/26
What's in Store for These 5 Medical Companies This Earnings Season?Zacks Investment Research • 02/23/26
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash GenerationSeeking Alpha • 02/20/26
Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026GlobeNewsWire • 02/19/26
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026PRNewsWire • 02/03/26
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart FailurePRNewsWire • 01/20/26
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self AdministrationGlobeNewsWire • 01/06/26
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory UpdatesZacks Investment Research • 12/19/25